Acumen Pharmaceuticals (ABOS) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Humacyte (HUMA) over the past year, gaining 11.7% versus a loss of 71.3%. Over five years, ABOS leads with a -84.5% price change compared with -95.4% for HUMA. Acumen Pharmaceuticals is the larger company by market cap ($151.9 million vs $124.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | HUMA |
|---|---|---|
| Share price | $2.10 | $0.4471 |
| Market cap | $151.87M | $124.20M |
| 1-day change | 0.00% | -5.34% |
| YTD return | -0.47% | -50.85% |
| 1-year return | +11.70% | -71.29% |
| 5-year return | -84.50% | -95.38% |
| EPS (TTM) | $-1.64 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $1.90 |
| 52-week low | $1.50 | $0.4367 |
| Distance from 52-week high | -41.67% | -76.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +261.90% | +264.57% |
| Average volume | 435.44K | 6.30M |
| Shares outstanding | 72.32M | 277.80M |
| Employees | 60 | 184 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed HUMA by 83.0 percentage points over the past year.
- The two companies sit in different sectors: Acumen Pharmaceuticals in Health Care and Humacyte in Healthcare.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Healthcare · Biotechnology · 184 employees
ABOS vs HUMA FAQ
Which is bigger, Acumen Pharmaceuticals or Humacyte?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $151.87M compared with $124.20M for Humacyte (HUMA).
Which stock has performed better over the past year, ABOS or HUMA?
ABOS returned +11.70% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Humacyte in the same industry?
No. Acumen Pharmaceuticals is in the Health Care sector, while Humacyte is in Healthcare.